B. Helfrich

1.7k total citations
27 papers, 1.4k citations indexed

About

B. Helfrich is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B. Helfrich has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B. Helfrich's work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). B. Helfrich is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). B. Helfrich collaborates with scholars based in United States, Italy and Canada. B. Helfrich's co-authors include Paul A. Bunn, Wilbur A. Franklin, Daniel C. Chan, Chan Zeng, Anna E. Barón, David Raben, Lynn E. Heasley, Fred R. Hirsch, Marileila Varella‐Garcia and Ting‐Chao Chou and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

B. Helfrich

27 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Helfrich United States 13 726 698 581 294 193 27 1.4k
Luka Milas United States 19 643 0.9× 489 0.7× 376 0.6× 257 0.9× 230 1.2× 41 1.4k
Shailaja Kalyankrishna United States 9 708 1.0× 694 1.0× 578 1.0× 185 0.6× 109 0.6× 9 1.3k
Marianna Gallo Italy 18 693 1.0× 588 0.8× 328 0.6× 319 1.1× 115 0.6× 37 1.3k
Charlotte Kopitz Germany 19 639 0.9× 981 1.4× 361 0.6× 787 2.7× 130 0.7× 40 1.7k
Filippo Petti United States 7 789 1.1× 829 1.2× 437 0.8× 298 1.0× 52 0.3× 8 1.4k
Simon A. Williams United States 15 344 0.5× 526 0.8× 185 0.3× 192 0.7× 101 0.5× 26 995
Yasir H. Ibrahim United States 12 828 1.1× 1.1k 1.5× 305 0.5× 249 0.8× 163 0.8× 22 1.6k
Marileila Varella‐Garcia United States 13 623 0.9× 618 0.9× 860 1.5× 277 0.9× 90 0.5× 16 1.4k
Vladimir Bilim Japan 25 583 0.8× 1.4k 2.0× 475 0.8× 397 1.4× 134 0.7× 81 2.1k

Countries citing papers authored by B. Helfrich

Since Specialization
Citations

This map shows the geographic impact of B. Helfrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Helfrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Helfrich more than expected).

Fields of papers citing papers by B. Helfrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Helfrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Helfrich. The network helps show where B. Helfrich may publish in the future.

Co-authorship network of co-authors of B. Helfrich

This figure shows the co-authorship network connecting the top 25 collaborators of B. Helfrich. A scholar is included among the top collaborators of B. Helfrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Helfrich. B. Helfrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hinz, Trista K., Emily K. Kleczko, Katherine R. Singleton, et al.. (2013). A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2(3). e39–e39. 203 indexed citations
2.
Weiss, Glen J., Lynne Bemis, Eri Nakajima, et al.. (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Annals of Oncology. 19(6). 1053–1059. 193 indexed citations
3.
Helfrich, B., et al.. (2008). 288 POSTER The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines. European Journal of Cancer Supplements. 6(12). 93–93. 1 indexed citations
4.
Chan, Dan, et al.. (2006). Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. Journal of Clinical Oncology. 24(18_suppl). 17114–17114. 4 indexed citations
5.
Helfrich, B., Barbara Frederick, David Raben, & Paul A. Bunn. (2006). 585 POSTER The dual specific Src/Abl kinase inhibitor AZD0530 inhibits in vitro growth and induces apoptosis in non-small cell lung cancer lines. European Journal of Cancer Supplements. 4(12). 177–177. 1 indexed citations
6.
Raben, David, B. Helfrich, Daniel C. Chan, et al.. (2005). The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer. Clinical Cancer Research. 11(2). 795–805. 194 indexed citations
7.
Raben, David, B. Helfrich, & Paul A. Bunn. (2004). Targeted therapies for non–small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. International Journal of Radiation Oncology*Biology*Physics. 59(2). S27–S38. 45 indexed citations
8.
Raben, David & B. Helfrich. (2004). Angiogenesis Inhibitors: A Rational Strategy for Radiosensitization in the Treatment of Non–Small-Cell Lung Cancer?. Clinical Lung Cancer. 6(1). 48–57. 23 indexed citations
9.
Hirsch, Fred R., Wilbur A. Franklin, Samir E. Witta, et al.. (2004). Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. Journal of Clinical Oncology. 22(14_suppl). 7027–7027. 5 indexed citations
10.
Hirsch, F. R., Wilbur A. Franklin, Samir E. Witta, et al.. (2004). Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. Journal of Clinical Oncology. 22(14_suppl). 7027–7027. 3 indexed citations
11.
Raben, David, B. Helfrich, Fortunato Ciardiello, & Paul A. Bunn. (2003). Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 41. 15–22. 7 indexed citations
12.
Raben, David, et al.. (2002). Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Review of Anticancer Therapy. 2(4). 461–471. 12 indexed citations
13.
Hirsch, Fred R., M. Varella-Garcia, Wilbur A. Franklin, et al.. (2002). Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. British Journal of Cancer. 86(9). 1449–1456. 205 indexed citations
14.
Bunn, Paul A., B. Helfrich, Wilbur A. Franklin, et al.. (2001). Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.. PubMed. 7(10). 3239–50. 131 indexed citations
15.
Helfrich, B., et al.. (1999). Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.. PubMed. 59(24). 6178–84. 167 indexed citations
16.
Bunn, P. A., David Chan, Lynn E. Heasley, et al.. (1997). Anti-growth factor therapy for lung cancer. Lung Cancer. 18. 10–11. 2 indexed citations
17.
18.
Cohen, Andrea J., P A Bunn, Wilbur A. Franklin, et al.. (1996). Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.. PubMed. 56(4). 831–9. 89 indexed citations
19.
Greeley, Elizabeth H., et al.. (1992). Radiant heat-induced hyperthermia in mice: in vivo effects on the immune system. International Journal of Hyperthermia. 8(2). 209–220. 1 indexed citations
20.
Ellis, Tom, et al.. (1989). Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.. The Journal of Immunology. 143(12). 4282–4286. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luka Milas Breakdown of academic impact, for papers by Shailaja Kalyankrishna Breakdown of academic impact, for papers by Marianna Gallo Breakdown of academic impact, for papers by Charlotte Kopitz Breakdown of academic impact, for papers by Filippo Petti Breakdown of academic impact, for papers by Simon A. Williams Breakdown of academic impact, for papers by Yasir H. Ibrahim Breakdown of academic impact, for papers by Marileila Varella‐Garcia Breakdown of academic impact, for papers by Vladimir Bilim
Rankless by CCL
2026